Pulmonary ct manifestations of COVID-19: changes within 2 weeks duration from presentation
Omar Sultan, Haider Najim Al-Tameemi, Dhia Mahdey Alghazali, Mohammed Abed, Muthana Naser Abu Ghniem, Dhaffer Abdullah Hawiji, Enas Abdulhussain Alwateefee, Hayder Dhajir Abbas Shubbar, Amal Hussein Tauah, Nisreen Mohammed Ibraheem, Ahmed D. Abdulwahab, Raad Hefdhi Abedtwfeq
Abstract
Abstract Background Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Chest computed tomography (CT) plays an essential role in the evaluation of COVID-19. This retrospective study aims to determine and compare the pulmonary changes in Iraqi patients with COVID-19 disease across the first two weeks after onset of symptoms using computerized tomography (CT) scan. Ninety-six patients with COVID-19 disease were enrolled in this study. Patients were divided into two groups according to the duration of symptoms (the first group has been scanned within the first week of presentation while the second group has been scanned in the second week). Results The CT findings in the first and second group were as follows: ground glass opacity (GGO) were 94.3% vs. 88.5%, consolidation were 25.7% vs. 34.6%, broncho vascular thickening were 18.6% vs. 7.7%, crazy paving appearance were 15.7% vs. 3.8%, tree-in-bud appearance were 4.3% vs. 10.7%, pulmonary nodules were 5.1% vs. 7.7%, and bronchiectasis were 5.5% vs. 7.7%. Pleural effusion and cavitation were seen only in the first group (2.9% and 1.4% respectively). The distribution of CT changes across the two groups were as follows: bilateral changes were 85.7% vs. 100%; central distribution were 11.4% vs. 11.5%; peripheral distribution were 64.3% vs. 42.3%, and diffuse (central and peripheral) distribution were 24.3% vs. 46.2% while multilobar distribution were 70% vs. 80.8%. Conclusion The type, extent, and distributions of pulmonary manifestations associated with COVID-19 infection are significantly different between the two groups who have been scanned in different stages of the disease.